Work

Pharmacokinetics of high-dose weekly Ambisome (liposomal amphotericin B) antifungal prophylaxis in pediatric bone marrow transplantation (BMT) patients

Year: 2005

Type: article

Abstract: Background: Disseminated fungal infection is a major cause of morbidity and mortality in children undergoing BMT. Prophylactic oral triazoles are limited by poor absorption, interindividual variation in metabolism, and hepatic toxicity. Ambisome is shown to produce higher plasma and tissue concentrations and has a better safety profile than the parent drug amphotericin B; however, it requires frequent intravenous administration. Both animal (murine models for Candida/Histoplasma) and human (adult) data show measurable plasma and tissue levels at 7 days after a single dose (2–20 mg/kg) of Ambisome.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2004.12.263